<DOC>
	<DOCNO>NCT00443339</DOCNO>
	<brief_summary>This evaluation effectiveness darbepoetin alpha treat anemia MDS patient International Prognostic Scoring System ( IPSS ) score low intermediate 1 .</brief_summary>
	<brief_title>Darbepoetin Alpha Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>Inclusion MDS IPSS low int-1 hemoglobin &lt; 10/dL . Study drug : Darbepoetin alfa ( Aranesp ) 500 microg every two week subcutaneously 12 week , combine filgrastim 300 microg twice weekly additional 12 week non responder . Response evaluate 12 week . Patients major minor erythroid response ( HI-E major minor accord IWG 2000 criterion ) continue Aranesp . In non-responders , additional 12 week Aranesp dosing , combine Filgrastim ( 300 ug twice weekly , adjust maintain WBC 5000 10000/mm3 ) propose . In case response , treatment continue total duration 24 month . If Hb level reach level &gt; 13 g/dl time , Aranesp discontinue Hb level less 12 g/dl . Aranesp resume 500 µg/injection every 3 week . Intervals injection increase one week every time lead Hb level &gt; 13 g/dl . The purpose dose adjustment reach Aranesp schedule allow maintenance Hb level 11 12 g/dl .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Darbepoetin alfa</mesh_term>
	<criteria>MDS follow subtypes : RA , RAS , RAEB marrow blast &lt; 10 % ( accord FAB ) , RA , RARS , RCMD , RAEB 1 , CMML 1 ≤ 10 % WBC count &lt; 13000/mm3 ( accord WHO classification ) Anemia , define Hb &lt; 10 g/dl RBC transfusion requirement absence cause anemia ( especially renal failure , iron , folate deficiency ) IPSS ≤ 1 ( ie IPSS low intermediate 1 ) EPO level &lt; 500 UI/L Ability perform physical test exercise tolerance No renal failure ( creatinine ≤ 120 % normal upper value center ) No underlie severe condition ECOG performance status score 0 , 1 , 2 Must 18 year age old time screen Written informed consent Therapy relate MDS MDS IPSS &gt; 1 ( int 2 high score ) Chronic myelomonocytic leukemia &gt; 10 % marrow blast WBC &gt; 13000/mm3 Uncontrolled systemic hypertension Cardiac condition : uncontrolled angina , congestive heart failure , uncontrolled cardiac arrhythmia Creatinine level &gt; 120 % upper normal value center . Clinically significant systemic infection chronic inflammatory disease ( eg , rheumatoid arthritis ) present time screen Serum folate ≤ 2.0 ng/mL vitamin B12 ≤ 200 pg/mL ( anemia relate nutritional deficiency ) Other cause anemia ( eg , hemolysis , bleeding , sickle cell anemia , renal disease ) Pregnant ( ie , positive βhCG test ) breast feed female subject Women childbearing potential use adequate contraceptive Known positive antibody response erythropoietic growth factor Known hypersensitivity darbepoetin alpha excipients , recombinant erythropoietins Patient unable understand protocol adequately follow . History seizures Previous history thrombotic event Concomitant treatment thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Myelodysplastic syndrome IPSS Low Int-1</keyword>
	<keyword>Anemia</keyword>
</DOC>